Update regarding COVID-19: We want you to know that we are here to support you during this time. Click here for more information.
Vyvanse is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients ages 6 and above. Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established.
This site is intended for US healthcare professionals only.
in Adults
(Ages 18 and Above)
in Children
(Ages 6-17)
Moderate to Severe
Please be advised that Shire has no control over the content or presentation of the site you are about to view.
Scroll for Full Prescribing Information
Continue to the Site